NCT00927069View on ClinicalTrials.gov

Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept

PHASE3CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

December 31, 2008

Conditions
Plaque Psoriasis
Interventions
DRUG

Adalimumab every other week

Adalimumab 40mg injection every other week for 24 weeks

DRUG

Adalimumab Every Week

Adalimumab 40mg injection every week for the last 12 weeks of study.

Trial Locations (12)

R3C 0N2

Winnipeg Clinic, Winnipeg

A1C 2H5

NewLab Clinical Research, St. John's

N5X 2P1

Mediprobe Research, London

N6A 3H7

The Guenther Dermatology Research center, London

L3P 1A8

Lynderm Research, Markham

L6K 1E1

Entralogix Inc., Oakville

M4V 1R1

Entralogix Clinical Group Inc., Toronto

N8W 5L7

Windsor Clinical Research Inc., Windsor

H7S 2C6

Innovaderm Research Laval Inc., Laval

H2K 4L5

Innovaderm Research Inc, Montreal

G1J 1X7

Centre de Recherche Clinique Martin Gilbert inc et Centre Dermatologie Maizerets, Québec

G1V 4X7

Centre de Recherches Dermatologiques du Quebec Metropolitain, Ste-Foy

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

Innovaderm Research Inc.

OTHER